Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vevorisertib in Advanced Solid Tumors
NCT02761694Phase 1Terminated
- Start
- Jun 2016
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of vevorisertib in solid tumor (12 arms). Primary endpoints: Number of Participants Who Experience One or More Adverse Events and Number of Participants Who Discontinue Study Treatment Due to an AE. Started Jun 2016; status: terminated.
02
Drugs
vevorisertib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02761694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02761694.